RT Journal Article
SR Electronic
T1 The COVID-19 herd immunity threshold is not low: A re-analysis of European data from spring of 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20242289
DO 10.1101/2020.12.01.20242289
A1 Spencer J. Fox
A1 Pratyush Potu
A1 Michael Lachmann
A1 Ravi Srinivasan
A1 Lauren Ancel Meyers
YR 2020
UL http://medrxiv.org/content/early/2020/12/03/2020.12.01.20242289.abstract
AB The recent publication of the Great Barrington Declaration (GBD), which calls for relaxing all public health interventions on young, healthy individuals, has brought the question of herd immunity to the forefront of COVID-19 policy discussions, and is partially based on unpublished research that suggests low herd immunity thresholds (HITs) of 10-20%. We re-evaluate these findings and correct a flawed assumption leading to COVID-19 HIT estimates of 60-80%. If policymakers were to adopt a herd immunity strategy, in which the virus is allowed to spread relatively unimpeded, we project that cumulative COVID-19 deaths would be five times higher than the initial estimates suggest. Our re-estimates of the COVID-19 HIT corroborate strong signals in the data and compelling arguments that most of the globe remains far from herd immunity, and suggest that abandoning community mitigation efforts would jeopardize the welfare of communities and integrity of healthcare systems.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge support from a CDC COVID-19 supplementary grant (U01IP001136-01-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data are available at https://github.com/pratyush16/VariationalSusceptibility https://github.com/pratyush16/VariationalSusceptibility